Abiomed (ABMD) Misses Q2 EPS by 4c; Maintains Revenue Outlook

October 27, 2016 7:54 AM EDT
Get Alerts ABMD Hot Sheet
Trade ABMD Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Abiomed (NASDAQ: ABMD) reported Q2 EPS of $0.20, $0.04 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $103 million versus the consensus estimate of $103.16 million.

GUIDANCE:

Abiomed maintains FY2017 revenue of $435-445 million, versus the consensus of $446.33 million.

For earnings history and earnings-related data on Abiomed (ABMD) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings, Guidance

Related Entities

Earnings

Add Your Comment